Non-immunoglobulin scaffolds: A focus on their targets

Trends in Biotechnology

Volumn 33, Issue 7, 2015, Pages 408-418

  Škrlec, Katja ^a   Štrukelj, Borut ^a,b   Berlec, Aleš ^a  

^a JO EF STEFAN INSTITUTE   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Antibody alternatives; Binders; Non immunoglobulin scaffolds

Indexed keywords

ANTIBODIES; BINDERS; COVALENT BONDS; DIAGNOSIS; DISEASES; PROTEINS;

CLINICAL TRIAL; DISULFIDE BONDS; INFLAMMATORY DISEASE; MULTIMERIZATION; POST-TRANSLATIONAL MODIFICATIONS; SINGLE-DOMAIN PROTEINS; STRUCTURE DETERMINATION; WESTERN BLOTTING;

SCAFFOLDS (BIOLOGY);

ABICIPAR PEGOL; DEPELESTAT; ECALLANTIDE; FLUORINE 18; GALLIUM 68; NON IMMUNOGLOBULIN SCAFFOLD; PEGDINETANIB; PEPTIDES AND PROTEINS; TECHNETIUM 99M; UNCLASSIFIED DRUG; NANOBODY; RECOMBINANT PROTEIN;

AGE RELATED MACULAR DEGENERATION; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; ANGIONEUROTIC EDEMA; APPLIED RESEARCH; BASIC RESEARCH; BIOSENSOR; BREAST CANCER; CANCER THERAPY; CARDIOVASCULAR DISEASE; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONFORMATIONAL TRANSITION; CROHN DISEASE; CYSTIC FIBROSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REGULATION; GENE SYNTHESIS; GLIOBLASTOMA; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; INFLAMMATORY BOWEL DISEASE; MICROARRAY ANALYSIS; NON SMALL CELL LUNG CANCER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON; PRIORITY JOURNAL; PROTEIN PROCESSING; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; DRUG DELIVERY SYSTEM;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; RECOMBINANT PROTEINS; SINGLE-DOMAIN ANTIBODIES;

EID: 84930927661     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2015.03.012     Document Type: Review

References (103)

1. Chames P., et al. Therapeutic antibodies: successes, limitations and hopes for the future. Br. J. Pharmacol. 2009, 157:220-233.
2. Hudson P.J., Souriau C. Engineered antibodies. Nat. Med. 2003, 9:129-134.
3. Banta S., et al. Replacing antibodies: engineering new binding proteins. Annu. Rev. Biomed. Eng. 2013, 15:93-113.
4. Dreier B., Pluckthun A. Rapid selection of high-affinity binders using ribosome display. Methods Mol. Biol. 2012, 805:261-286.
5. Lofblom J., et al. Non-immunoglobulin based protein scaffolds. Curr. Opin. Biotechnol. 2011, 22:843-848.
6. Gronwall C., Stahl S. Engineered affinity proteins-generation and applications. J. Biotechnol. 2009, 140:254-269.
7. Jost C., Pluckthun A. Engineered proteins with desired specificity: DARPins, other alternative scaffolds and bispecific IgGs. Curr. Opin. Struct. Biol. 2014, 27C:102-112.
8. Gebauer M., Skerra A. Engineered protein scaffolds as next-generation antibody therapeutics. Curr. Opin. Chem. Biol. 2009, 13:245-255.
9. Hey T., et al. Artificial, non-antibody binding proteins for pharmaceutical and industrial applications. Trends Biotechnol. 2005, 23:514-522.
10. Binz H.K., et al. Engineering novel binding proteins from nonimmunoglobulin domains. Nat. Biotechnol. 2005, 23:1257-1268.
11. Sennhauser G., et al. Drug export pathway of multidrug exporter AcrB revealed by DARPin inhibitors. PLoS Biol. 2007, 5:e7.
12. Silverman J., et al. Multivalent Avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat. Biotechnol. 2005, 23:1556-1561.
13. Byla P., et al. Selection of a novel and highly specific tumor necrosis factor alpha (TNFalpha) antagonist: insight from the crystal structure of the antagonist-TNFalpha complex. J. Biol. Chem. 2010, 285:12096-12100.
14. Silacci M., et al. Linker length matters, Fynomer-Fc fusion with an optimized linker displaying picomolar IL-17A inhibition potency. J. Biol. Chem. 2014, 289:14392-14398.
15. Zahnd C., et al. A designed ankyrin repeat protein evolved to picomolar affinity to Her2. J. Mol. Biol. 2007, 369:1015-1028.
16. Gostring L., et al. Cellular effects of HER3-specific Affibody molecules. PLoS ONE 2012, 7:e40023.
17. Getmanova E.V., et al. Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro. Chem. Biol. 2006, 13:549-556.
18. Walsh G. Biopharmaceutical benchmarks 2014. Nat. Biotechnol. 2014, 32:992-1000.
19. Ding L., et al. Small sized EGFR1 and HER2 specific bifunctional antibody for targeted cancer therapy. Theranostics 2015, 5:378-398.
20. Krause D.S., Van Etten R.A. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 2005, 353:172-187.
21. Lemmon M.A., Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010, 141:1117-1134.
22. Flynn J.F., et al. Anti-EGFR therapy: mechanism and advances in clinical efficacy in breast cancer. J. Oncol. 2009, 2009:526963.
23. Mross K., et al. First-in-human phase I study of PRS-050 (Angiocal), an Anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors. PLoS ONE 2013, 8:e83232.
24. Stahl A., et al. Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications. Angiogenesis 2013, 16:101-111.
25. Mamluk R., et al. Anti-tumor effect of CT-322 as an Adnectin inhibitor of vascular endothelial growth factor receptor-2. MAbs 2010, 2:199-208.
26. Allen J.E., et al. Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexes. Mol. Cancer Ther. 2012, 11:2087-2095.
27. Swers J.S., et al. Multivalent scaffold proteins as superagonists of TRAIL receptor 2-induced apoptosis. Mol. Cancer Ther. 2013, 12:1235-1244.
28. Gebauer M., et al. Combinatorial design of an Anticalin directed against the extra-domain b for the specific targeting of oncofetal fibronectin. J. Mol. Biol. 2013, 425:780-802.
29. Benson J.M., et al. Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab. Nat. Biotechnol. 2011, 29:615-624.
30. Ramamurthy V., et al. Structures of adnectin/protein complexes reveal an expanded binding footprint. Structure 2012, 20:259-269.
31. Desmet J., et al. Structural basis of IL-23 antagonism by an Alphabody protein scaffold. Nat. Commun. 2014, 5:5237.
32. Kuchar M., et al. Human interleukin-23 receptor antagonists derived from an albumin-binding domain scaffold inhibit IL-23-dependent ex vivo expansion of IL-17-producing T-cells. Proteins 2014, 82:975-989.
33. Qu N., et al. Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22, and IL-23, in inflammatory diseases. Clin. Dev. Immunol. 2013, 2013:968549.
34. Lee J.J., et al. A high-affinity protein binder that blocks the IL-6/STAT3 signaling pathway effectively suppresses non-small cell lung cancer. Mol. Ther. 2014, 22:1254-1265.
35. Jonsson A., et al. Generation of tumour-necrosis-factor-alpha-specific Affibody molecules capable of blocking receptor binding in vitro. Biotechnol. Appl. Biochem. 2009, 54:93-103.
36. Ravnikar M., et al. Engineered lactic acid bacterium Lactococcus lactis capable of binding antibodies and tumor necrosis factor alpha. Appl. Environ. Microbiol. 2010, 76:6928-6932.
37. Hohlbaum, A. et al. Pieris AG. Tear lipocalin in muteins binding IL-4R alpha, WO 2011154420 A3.
38. Roberts B.L., et al. Protease inhibitor display M13 phage: selection of high-affinity neutrophil elastase inhibitors. Gene 1992, 121:9-15.
39. Dunlevy F.K., et al. Anti-inflammatory effects of DX-890, a human neutrophil elastase inhibitor. J. Cyst. Fibros. 2012, 11:300-304.
40. Gronwall C., et al. Selection and characterization of Affibody ligands binding to Alzheimer amyloid beta peptides. J. Biotechnol. 2007, 128:162-183.
41. Hoyer W., et al. Stabilization of a beta-hairpin in monomeric Alzheimer's amyloid-beta peptide inhibits amyloid formation. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:5099-5104.
42. Dennis M.S., et al. Potent and selective Kunitz domain inhibitors of plasma kallikrein designed by phage display. J. Biol. Chem. 1995, 270:25411-25417.
43. Grebenchtchikov N., et al. Engineered human lipocalin as an antibody mimetic: application to analysis of the small peptide hormone hepcidin. Clin. Chem. 2014, 60:897-899.
44. Mitchell T., et al. Pharmacologic profile of the Adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering. J. Pharmacol. Exp. Ther. 2014, 350:412-424.
45. Lofblom J., et al. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett. 2010, 584:2670-2680.
46. 111In-labeled synthetic anti-HER2 Affibody molecules. Bioconjug. Chem. 2012, 23:1661-1670.
47. 68Ga-labeled Affibody molecules. J. Nucl. Med. 2010, 51:892-897.
48. Miao Z., et al. Protein scaffold-based molecular probes for cancer molecular imaging. Amino Acids 2011, 41:1037-1047.
49. Tolmachev V., et al. Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy. Expert Opin. Biol. Ther. 2007, 7:555-568.
50. Nordberg E., et al. Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding Affibody molecule. Nucl. Med. Biol. 2007, 34:609-618.
51. 89Zr-PRS-110 PET tracer. J. Nucl. Med. 2014, 55:665-671.
52. Gong H., et al. In vivo imaging of xenograft tumors using an epidermal growth factor receptor-specific Affibody molecule labeled with a near-infrared fluorophore. Neoplasia 2010, 12:139-149.
53. Lee S.B., et al. Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging. Clin. Cancer Res. 2008, 14:3840-3849.
54. Kinoshita M., et al. MR molecular imaging of HER-2 in a murine tumor xenograft by SPIO labeling of anti-HER-2 Affibody. Contrast Media Mol. Imaging 2010, 5:18-22.
55. Yang H., et al. Nanobubble-Affibody: novel ultrasound contrast agents for targeted molecular ultrasound imaging of tumor. Biomaterials 2014, 37C:279-288.
56. Straw S., et al. Proof of concept study to identify candidate biomarkers of fibrosis using high throughput peptide aptamer microarray and validate by enzyme linked immunosorbant assay. J. Biomed. Sci. Eng. 2013, 06:32-42.
57. Miranda F.F., et al. Reagentless fluorescent biosensors from artificial families of antigen binding proteins. Biosens. Bioelectron. 2011, 26:4184-4190.
58. Brient-Litzler E., et al. Knowledge-based design of reagentless fluorescent biosensors from a designed ankyrin repeat protein. Protein Eng. Des. Sel. 2010, 23:229-241.
59. Johnson A., et al. Sensitive affimer and antibody based impedimetric label-free assays for C-reactive protein. Anal. Chem. 2012, 84:6553-6560.
60. Phelan M.L., Nock S. Generation of bioreagents for protein chips. Proteomics 2003, 3:2123-2134.
61. Renberg B., et al. Affibody protein capture microarrays: synthesis and evaluation of random and directed immobilization of affibody molecules. Anal. Biochem. 2005, 341:334-343.
62. Zadravec P., et al. Improvement of LysM-mediated surface display of designed ankyrin repeat proteins (DARPins) in recombinant and nonrecombinant strains of Lactococcus lactis and Lactobacillus species. Appl. Environ. Microbiol. 2015, 81:2098-2106.
63. Lyakhov I., et al. HER2- and EGFR-specific affiprobes: novel recombinant optical probes for cell imaging. Chembiochem 2010, 11:345-350.
64. Lundberg E., et al. Selection and characterization of Affibody ligands to the transcription factor c-Jun. Biotechnol. Appl. Biochem. 2009, 52:17-27.
65. Bukowska M.A., Grutter M.G. New concepts and aids to facilitate crystallization. Curr. Opin. Struct. Biol. 2013, 23:409-416.
66. Seeger M.A., et al. Tuning the drug efflux activity of an ABC transporter in vivo by in vitro selected DARPin binders. PLoS ONE 2012, 7:e37845.
67. Schweizer A., et al. Inhibition of caspase-2 by a designed ankyrin repeat protein: specificity, structure, and inhibition mechanism. Structure 2007, 15:625-636.
68. Flutsch A., et al. Specific targeting of human caspases using designed ankyrin repeat proteins. Biol. Chem. 2014, 395:1243-1252.
69. Scholz O., et al. G-quadruplexes are specifically recognized and distinguished by selected designed ankyrin repeat proteins. Nucleic Acids Res. 2014, 42:9182-9194.
70. Kaiser P.D., et al. Recent progress in generating intracellular functional antibody fragments to target and trace cellular components in living cells. Biochim. Biophys. Acta 2014, 1844:1933-1942.
71. Kummer L., et al. Structural and functional analysis of phosphorylation-specific binders of the kinase ERK from designed ankyrin repeat protein libraries. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:E2248-E2257.
72. Grimm S., et al. Monitored whole gene in vitro evolution of an anti-hRaf-1 Affibody molecule towards increased binding affinity. N. Biotechnol. 2012, 29:534-542.
73. Kummer L., et al. Knowledge-based design of a biosensor to quantify localized ERK activation in living cells. Chem. Biol. 2013, 20:847-856.
74. Gulyani A., et al. A biosensor generated via high-throughput screening quantifies cell edge Src dynamics. Nat. Chem. Biol. 2011, 7:437-444.
75. Heu W., et al. Protein binder for affinity purification of human immunoglobulin antibodies. Anal. Chem. 2014, 86:6019-6025.
76. Gunneriusson E., et al. Affinity maturation of a Taq DNA polymerase specific Affibody by helix shuffling. Protein Eng. 1999, 12:873-878.
77. Nilvebrant J., et al. Development and characterization of small bispecific albumin-binding domains with high affinity for ErbB3. Cell. Mol. Life Sci. 2013, 70:3973-3985.
78. Tiede C., et al. Adhiron: a stable and versatile peptide display scaffold for molecular recognition applications. Protein Eng. Des. Sel. 2014, 27:145-155.
79. Varadamsetty G., et al. Designed Armadillo repeat proteins: library generation, characterization and selection of peptide binders with high specificity. J. Mol. Biol. 2012, 424:68-87.
80. Ebersbach H., et al. Affilin-novel binding molecules based on human gamma-B-crystallin, an all beta-sheet protein. J. Mol. Biol. 2007, 372:172-185.
81. Hoffmann A., et al. New binding mode to TNF-alpha revealed by ubiquitin-based artificial binding protein. PLoS ONE 2012, 7:e31298.
82. Stadler L.K., et al. Structure-function studies of an engineered scaffold protein derived from Stefin A. II: Development and applications of the SQT variant. Protein Eng. Des. Sel. 2011, 24:751-763.
83. Krehenbrink M., et al. Artificial binding proteins (Affitins) as probes for conformational changes in secretin PulD. J. Mol. Biol. 2008, 383:1058-1068.
84. Diem M.D., et al. Selection of high-affinity Centyrin FN3 domains from a simple library diversified at a combination of strand and loop positions. Protein Eng. Des. Sel. 2014, 27:419-429.
85. Binz H.K., et al. High-affinity binders selected from designed ankyrin repeat protein libraries. Nat. Biotechnol. 2004, 22:575-582.
86. Seeger M.A., et al. Design, construction, and characterization of a second-generation DARP in library with reduced hydrophobicity. Protein Sci. 2013, 22:1239-1257.
87. Schilling J., et al. From DARPins to LoopDARPins: novel LoopDARPin design allows the selection of low picomolar binders in a single round of ribosome display. J. Mol. Biol. 2014, 426:691-721.
88. Steemson J.D., et al. Tracking molecular recognition at the atomic level with a new protein scaffold based on the OB-fold. PLoS ONE 2014, 9:e86050.
89. Lee S.C., et al. Design of a binding scaffold based on variable lymphocyte receptors of jawless vertebrates by module engineering. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:3299-3304.
90. Wetzel S.K., et al. Folding and unfolding mechanism of highly stable full-consensus ankyrin repeat proteins. J. Mol. Biol. 2008, 376:241-257.
91. Engfeldt T., et al. Chemical synthesis of triple-labelled three-helix bundle binding proteins for specific fluorescent detection of unlabelled protein. Chembiochem 2005, 6:1043-1050.
92. Stern L.A., et al. Alternative non-antibody protein scaffolds for molecular imaging of cancer. Curr. Opin. Chem. Eng. 2013, 2:425-432.
93. Binder U., Skerra A. Half-life extension of therapeutic proteins via genetic fusion to recombinant PEG mimetics. Therapeutic Proteins: Strategies to Modulate Their Plasma Half-lives 2012, 63-80. Wiley-Blackwell. R. Kontermann (Ed.).
94. Kontermann R.E. Strategies for extended serum half-life of protein therapeutics. Curr. Opin. Biotechnol. 2011, 22:868-876.
95. Emanuel S.L., et al. A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor. MAbs 2011, 3:38-48.
96. Schlehuber S., Skerra A. Duocalins: engineered ligand-binding proteins with dual specificity derived from the lipocalin fold. Biol. Chem. 2001, 382:1335-1342.
97. Jost C., et al. Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer cells via binding to the extracellular domain of HER2. Structure 2013, 21:1979-1991.
98. Brack S., et al. A bispecific HER2-targeting FynomAb with superior antitumor activity and novel mode of action. Mol. Cancer Ther. 2014, 13:2030-2039.
99. Martin-Killias P., et al. A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity. Clin. Cancer Res. 2011, 17:100-110.
100. Puri A., et al. HER2-specific affibody-conjugated thermosensitive liposomes (Affisomes) for improved delivery of anticancer agents. J. Liposome Res. 2008, 18:293-307.
101. Shishido T., et al. Affibody-displaying bionanocapsules for specific drug delivery to HER2-expressing cancer cells. Bioorg. Med. Chem. Lett. 2010, 20:5726-5731.
102. Plückthun A. Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy. Annu. Rev. Pharmacol. Toxicol. 2015, 55:489-511.
103. Desmet, J. et al. Complix. Alphabodies specifically binding to cytokines or growth factors and/or cytokine or growth factor receptors, WO 2012093172 A1.